Related Experiment Video

Updated: Dec 24, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K

Non-coding RNAs and Ischemic Cardiovascular Diseases

Tarik Smani1,2, Isabel Mayoral-Gonzalez3,4, Isabel Galeano-Otero3

  • 1Department of Medical Physiology and Biophysics, Institute of Biomedicine of Seville (IBiS), University of Seville, Seville, Spain. tasmani@us.es.

Advances in Experimental Medicine and Biology
|April 15, 2020
PubMed

Insights

Non-coding RNAs (ncRNAs) show promise as diagnostic and prognostic biomarkers for Ischemic Heart Disease (IHD). Further research is needed to discover and characterize more functional ncRNAs for IHD treatment and management.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Genetics

Background:

  • Ischemic Heart Disease (IHD) is a major cause of global morbidity and mortality.
  • It arises from an imbalance between myocardial blood supply and demand.
  • Early diagnosis and prognosis are crucial for effective IHD management.

Purpose of the Study:

  • To explore the role of non-coding RNAs (ncRNAs) in Ischemic Heart Disease (IHD).
  • To identify potential ncRNA biomarkers for IHD diagnosis and prognosis.
  • To discuss current knowledge and future directions for ncRNAs in IHD research.

Main Methods:

  • Review of current scientific literature on ncRNAs and IHD.
  • Analysis of the functional roles of specific ncRNAs in cardiovascular conditions.
  • Discussion of potential therapeutic and diagnostic applications of ncRNAs.

Main Results:

  • Non-coding RNAs (ncRNAs) are emerging as significant factors in IHD.
  • Several ncRNAs have demonstrated potential as biomarkers for IHD.
  • The full spectrum of functional ncRNAs in IHD remains to be discovered.

Conclusions:

  • ncRNAs represent a promising area for developing novel diagnostic and prognostic tools for IHD.
  • Further investigation into ncRNA function is essential for advancing IHD treatment strategies.
  • Targeting ncRNAs may offer new therapeutic avenues for cardiovascular diseases.

Keywords:
CardioprotectionIschemia and reperfusionNon-coding RNAsRNAs

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

6.9K
Preparation of a Non-Cardiomyocyte Cell Suspension for Single-Cell RNA Sequencing from a Post-Myocardial Infarction Adult Mouse Heart05:54

Preparation of a Non-Cardiomyocyte Cell Suspension for Single-Cell RNA Sequencing from a Post-Myocardial Infarction Adult Mouse Heart

Published on: February 3, 2023

2.5K

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
294
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K